Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 25, 2026
TickeronGET DAILY SIGNALS
State Street SPDR S&P Biotech ETF (XBI) Navigates -3.7% Decline in Consolidation Phase

State Street SPDR S&P Biotech ETF (XBI) Navigates -3.7% Decline in Consolidation Phase

Key Takeaways

  • XBI tracks the S&P Biotechnology Select Industry Index with a modified equal-weight approach, which limits heavy concentration in the largest biopharma names.
  • The fund holds about 160 biotechnology stocks, carries a 0.35% net expense ratio, and manages roughly $10 billion in assets.
  • Equal weighting shifts exposure toward smaller and mid-sized biotech firms, increasing sensitivity to clinical developments and merger activity compared with cap-weighted alternatives.
  • Biotechnology remains a high-volatility area influenced by drug approvals, trial results, regulatory changes, and interest-rate expectations.
  • Over the past 30 days XBI fell about 3.7%, while the trailing quarter showed a modest decline, pointing to consolidation rather than a clear trend.
  • For more details on this ticker, review its Price Targets and Forecast pages for technical levels and forward signals.

Getting to Know the XBI ETF

The State Street SPDR S&P Biotech ETF aims to match the performance of the S&P Biotechnology Select Industry Index before fees and expenses. Launched in January 2006, XBI is a passive fund offering broad access to the U.S. biotechnology sector. Its modified equal-weight structure sets it apart from market-cap-weighted peers by spreading allocations more evenly and reducing the pull of the biggest biopharma companies.

The portfolio includes roughly 160 stocks, with nearly all assets in biotechnology. Because of the equal-weight design, individual holdings stay small and adjust regularly during rebalancing. Recent top positions have featured MRNA, TWST, NTRA, and HALO, each typically making up a low single-digit share of the fund. The net expense ratio stands at 0.35%. This setup gives smaller and mid-cap companies more influence, where prices often react sharply to clinical events, partnerships, or M&A activity. I also checked this using Tickeron’s AI Screener to compare XBI against similar sector funds.

The Broader Biotech Environment

Biotechnology sits in a unique spot within healthcare. Its revenues depend more on scientific milestones such as regulatory approvals, pipeline updates, and reimbursement decisions than on the overall economy. Supportive long-term drivers include an aging population, growing chronic disease rates, and progress in areas like cell and gene therapy, antibody-drug conjugates, and RNA medicines.

At the same time, the sector reacts to macroeconomic shifts. Many biotech firms carry large capital needs and near-term losses, so their valuations can swing with changes in interest-rate outlooks. Higher borrowing costs for longer tend to compress future cash-flow values, while signs of easing can lift risk appetite in the small- and mid-cap names that dominate XBI. Policy discussions on drug pricing and regulatory frameworks add another layer of uncertainty.

Recent Moves and Positioning

XBI has stayed within a wide consolidation range lately. Over the last 30 days the fund declined roughly 3.7%, and the trailing-quarter performance was modestly negative, reflecting range-bound trading rather than a sustained direction. Volatility inside the period has been noticeable, including a strong August advance that was largely reversed by later pullbacks.

This behavior aligns with the fund’s makeup. Equal weighting reduces the stabilizing effect of large, cash-generating biopharma names, so XBI feels more of the impact from company-specific catalysts in its smaller holdings. Clinical data releases, equity offerings, and M&A news can produce sizable moves that add up at the fund level. Sector rotation between growth and value areas inside healthcare has also played a role, as investors balance innovation prospects against uncertain rates and regulatory questions. One thing that stands out is how quickly sentiment can shift on macro news.

Factors to Watch in 2026

Several elements will likely shape XBI going forward. The path of interest rates and inflation remains central because of the sector’s reliance on discounted future cash flows. A steady easing cycle could support risk appetite in small- and mid-cap biotechnology, while ongoing inflation pressures could dampen enthusiasm. The timing and quality of clinical readouts from major holdings will matter as well, since approvals and trial results drive single-stock moves that affect the overall fund.

Regulatory updates on drug pricing and merger reviews present both risks and opportunities. Capital flows into biotech ETFs and competition among similar products will influence demand. Monitoring earnings from larger holdings can still provide useful valuation context even in an equal-weight setup. No single factor is expected to dominate; instead, the fund’s direction will hinge on how macroeconomic conditions, innovation milestones, and investor positioning interact across the biotechnology space. I’m watching this closely through a combination of fundamental review and technical signals.

Exploring Biotech Opportunities with Tickeron Tools

In my own research process I often turn to Tickeron’s AI Screener when scanning the biotechnology space. The platform lets me apply technical indicators, fundamentals, volatility filters, AI signals, and custom criteria to surface candidates efficiently. It has helped me narrow broad watchlists into more focused ideas without replacing my overall analysis. For anyone evaluating a volatile sector like this, the tool offers a practical way to organize data and spot patterns worth further review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XBI

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


XBI in downward trend: price dove below 50-day moving average on November 12, 2026

XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 50 of 53 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 77 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 45 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the State Street SPDR S&P Biotech ETF (XBI) ETF is 15.28B. The market cap for tickers in the group ranges from 136.65M to 514.78B. ABBV holds the highest valuation in this group at 514.78B. The lowest valued company is CMPX at 136.65M.

High and low price notable news

The average weekly price growth across all stocks in the State Street SPDR S&P Biotech ETF (XBI) ETF was -7%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was 11%. SPRY experienced the highest price growth at 14%, while CADL experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the State Street SPDR S&P Biotech ETF (XBI) ETF was -25%. For the same stocks of the ETF, the average monthly volume growth was -12% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 45
Price Growth Rating: 54
SMR Rating: 87
Profit Risk Rating: 79
Seasonality Score: 15 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.